이펙터 테라퓨틱스(EFTR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.00 (-75.00%), 시가총액 $0.00B, 52주 최저~최고 $0.00 ~ $0.00.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer In
이펙터 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이펙터 테라퓨틱스의 현재 주가는 $0.00 (-75.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이펙터 테라퓨틱스의 시가총액은 약 $0.00B입니다.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate inc